About BioTech Exec Leen Kawas
Leen Kawas is a prominent figure in the biotech industry who has made significant contributions to neuroscience. She is the CEO and President of M3 Biotechnology, a company dedicated to developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
Kawas’ educational background includes a PhD in neuroscience from the University of Washington and an MBA from the Kellogg School of Management. With her knowledge and expertise, she has been able to create a unique approach to the treatment of neurological diseases.
Under Kawas’ leadership, M3 Biotechnology has developed a revolutionary drug delivery system that targets the brain in a specific and effective way. This system uses a small drug called NDX-1017 that can cross the blood-brain barrier, a natural defence mechanism that protects the brain from foreign substances. The drug can treat various neurodegenerative diseases by targeting specific areas of the brain.
In addition to her work at M3 Biotechnology, Leen Kawas has received numerous awards and recognition for her contributions to the biotech industry. She was named one of the Puget Sound Business Journal’s 40 Under 40 in 2017 and recognized by GeekWire as one of the Seattle 10 in 2018. Kawas has also been featured in Forbes and other prominent publications.
As a woman in a male-dominated industry, Leen Kawas is a trailblazer who has broken down barriers and inspired many others to pursue careers in biotech. She is passionate about promoting diversity and inclusivity in the workplace and strongly advocates for women in science.
Leen Kawas’ dedication and innovative approach to treating neurodegenerative diseases have made her a respected leader in the biotech industry. Her work has the potential to transform the lives of millions of people around the world who are affected by neurological conditions.